#Saudi Arabia #Riyadh #Nanoscope Therapeutics #Vision Restoration #MCO-010

Nanoscope Therapeutics Secures Orphan Drug Designation in Saudi Arabia

Nanoscope Therapeutics, Inc., a pioneering biotechnology company, proudly announces its recent acquisition of Orphan Drug Designation in Saudi Arabia for its innovative therapy, MCO-010. This groundbreaking therapy is aimed at treating patients struggling with inherited retinal dystrophies (IRDs) and significant vision loss. The designation is a significant milestone that not only enhances Nanoscope’s global regulatory presence but also highlights the growing recognition of its proprietary Multi-Characteristic Opsin (MCO) platform as a potential frontrunner in optogenetic therapies for restoring vision.

Dr. Samarendra Mohanty, President and Chief Scientific Officer of Nanoscope Therapeutics, remarked on the development, stating, "The progress we're making with MCO-010 as a disease-neutral optogenetic treatment marks a promising advance in our commitment to bringing effective therapies to patients around the globe, particularly in regions historically limited in access to advanced retinal treatments."

Building a Global Regulatory Pathway

The Orphan Drug Designation in Saudi Arabia adds to a series of significant regulatory accomplishments for MCO-010 across major markets, including the United States, Japan, and Europe. In the U.S., this therapy has earned several designations such as Orphan Drug and Fast Track status for retinitis pigmentosa and multiple designations for Stargardt disease, showcasing its advanced stage of development.

In Japan, the Ministry of Health, Labour and Welfare has recognized MCO-010 with both Sakigake (Pioneering Regenerative Medical Product) and Orphan Drug designations, emphasizing its innovative approach in treating IRDs within the country. These distinct recognitions facilitate an accelerated regulatory pathway, ensuring prioritized consultations and potential expedited review timelines.

Moreover, across Europe, MCO-010 has gained five Orphan designations from the European Medicines Agency (EMA), affirming a disease-agnostic regulatory strategy in tackling multiple conditions linked to IRDs. The urgency for effective treatments is paramount; IRDs are a collection of rare progressive diseases that can lead to serious vision impairment or blindness, with limited options currently available for patients.

The MCO Therapy Platform: A New Hope

MCO-010 is part of a unique, one-time intravitreal therapy developed to restore vision for individuals with degenerated photoreceptors. This approach capitalizes on activating dense bipolar retinal cells to become light-sensitive, utilizing neuroelements that remain functioning after the loss of photoreceptors, all without necessitating an invasive surgical procedure or extensive genetic examinations. As such, the MCO treatment is set to be implemented seamlessly within existing retinal clinical practices, making it broadly applicable to a wide array of patients.

About Nanoscope Therapeutics, the company's overarching mission is to innovate and provide disease-agnostic optogenetic therapies targeting millions afflicted by retinal degenerative diseases. Encouraging results from the RESTORE Phase 2b/3 study are pivotal, as the company is navigating a rolling Biologics License Application (BLA) submission process with the FDA, aiming for MCO-010 to become a standard one-time treatment available in offices for retinitis pigmentosa patients.

Furthermore, Nanoscope has initiated the STARLIGHT Phase 2 clinical trial, also involving MCO-010 in Stargardt disease, set to expand further with a Phase 3 registrational trial scheduled to launch in 2026.

The journey of Nanoscope Therapeutics is marked not only by its achievements in regulatory frameworks but also by its promise to deliver transformative therapies to those impacted by vision loss. With the Orphan Drug Designation in Saudi Arabia, the future looks bright as the company continues to advance its strategies for optogenetic therapy and tackle the primary causes of blindness worldwide.